ANI Pharmaceuticals (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 459 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Thomas Andrew Rowland sold 459 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $79.21, for a total value of $36,357.39. Following the completion of the transaction, the senior vice president owned 38,271 shares in the company, valued at approximately $3,031,445.91. The trade was a 1.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Thomas Andrew Rowland also recently made the following trade(s):

• On Wednesday, March 11th, Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $74.91, for a total value of $357,470.52.

ANI Pharmaceuticals Stock Up 1.7%

Shares of NASDAQ:ANIP opened at $80.88 on Thursday. The business’s 50 day simple moving average is $77.19 and its two-hundred day simple moving average is $80.60. The firm has a market cap of $1.81 billion, a P/E ratio of 20.48 and a beta of 0.46. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a 52-week low of $56.71 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current fiscal year.

ANI Pharmaceuticals News Roundup

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat first-quarter expectations, reporting $2.05 EPS versus the $1.28 consensus and revenue of $237.46 million versus $207.63 million expected. The company also raised/affirmed FY2026 guidance at $9.19-$9.69 EPS, supporting the case for continued fundamental strength.
• Positive Sentiment: Analyst sentiment remains constructive, with upgrades from Zacks Research and Wall Street Zen and a consensus “Moderate Buy” rating plus a $107.33 target price, which can help support investor confidence.
• Neutral Sentiment: ANI Pharmaceuticals published an updated investor presentation highlighting non-GAAP metrics, which may be viewed as a routine disclosure but does not appear to materially change the near-term outlook on its own. ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
• Negative Sentiment: Several insiders sold shares, including CEO Nikhil Lalwani, who sold 55,000 shares, along with sales by directors and executives Patrick D. Walsh, Meredith Cook, Ori Gutwerg, and Thomas Andrew Rowland. Heavy insider selling can raise caution among investors, even if some transactions were pre-planned.
• Negative Sentiment: A separate report said Global Alpha dumped 229,000 ANIP shares worth about $17.9 million, adding to concerns that some large holders may be trimming exposure. Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Guggenheim increased their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. Finally, Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $107.33.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after acquiring an additional 27,598 shares during the last quarter. State Street Corp increased its position in shares of ANI Pharmaceuticals by 2.2% during the fourth quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after acquiring an additional 15,496 shares during the last quarter. UBS Group AG increased its position in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after acquiring an additional 185,172 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of ANI Pharmaceuticals by 8.9% during the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after acquiring an additional 43,523 shares during the last quarter. Finally, Tang Capital Management LLC increased its position in shares of ANI Pharmaceuticals by 51.6% during the fourth quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock valued at $38,005,000 after acquiring an additional 163,937 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.